Article | September 6, 2018

How A New Cell Therapy Platform Helps Scale Up Manufacturing To Reach More Patients

Source: Cytiva
Cell

In August 2016, doctors gave 33-year-old Nicole Gularte three to four weeks to live.

She had relapsed with acute lymphoblastic leukemia (ALL) seven times over the last decade. ALL is a type of fast-moving blood cancer that causes the bone marrow to produce too many immature white blood cells, which can spread the disease to other parts of the body. If left untreated, ALL is deadly.

Nicole had exhausted all her treatment options – except one.

Her last hope was an experimental treatment known as CAR T-cell therapy.

In cell therapy, immune cells (T-cells) are extracted from the patient and sent to a manufacturing facility where they are carefully reengineered and reprogrammed to identify and destroy cancer cells. The reprogrammed T-cells are then sent back to the patient’s treatment location, where they are injected back into the patient’s bloodstream to find the disease and remove it from the body.

Nicole completed her CAR T-cell treatment on October 4, 2016. Five days later, she was declared cancer-free.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: